Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects taking ipilimumab, as an immediate or
delayed treatment, following completion of sipuleucel-T (SipT) treatment, has on patients and
their prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bristol-Myers Squibb Dendreon M.D. Anderson Cancer Center